Navigation Links
WuXi PharmaTech Announces Purchase of Ordinary Shares from General Atlantic
Date:2/15/2012

SHANGHAI, Feb. 15, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company, with operations in China and the United States, announced that today it had in a negotiated transaction agreed to purchase from investment funds affiliated with global growth investor General Atlantic LLC ("General Atlantic") all of the WuXi ordinary shares General Atlantic received on February 12, 2012, following the conversion in full of the $35 million principal amount of convertible notes plus accrued interest of approximately $864,000 held by General Atlantic. The per-ADS equivalent purchase price of $13 was established based on a discount of slightly over 5% of the ADS closing price on February 13, 2012. The transaction was reviewed and approved by the disinterested members of the audit committee of WuXi's board of directors. WuXi expects the transaction to close on or about February 24, 2012. WuXi will use existing cash balances to pay for the transaction.

In February 2007, third-party investors, including General Atlantic, purchased $40 million principal amount of convertible notes from WuXi, with the notes maturing on February 9, 2012. In 2008, $5 million principal amount of notes were converted into ordinary shares. On February 7, 2012, General Atlantic elected to convert the remaining $35 million principal amount of notes plus accrued interest of approximately $864,000 into 22,771,000 ordinary shares at a conversion price of $1.575 per ordinary share, equivalent to 2,846,375 ADSs and a per-ADS conversion price of $12.60.

The potential impact of the conversion of the notes to ordinary shares has been reflected in the earnings per share calculations in WuXi's previous financial reporting, in accordance with generally accepted accounting principles. With WuXi's purchase of these shares t
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. WuXi PharmaTech Schedules Fourth-Quarter 2011 Earnings Release
2. WuXi PharmaTech Provides Update of 2011 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
3. WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards
4. WuXi PharmaTech Schedules Third-Quarter 2011 Earnings Release
5. WuXi PharmaTech Acquires China-Based Clinical Research Services Companies
6. WuXi PharmaTech Announces Second Quarter 2011 Results
7. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
8. WuXi PharmaTech Schedules Second-Quarter 2011 Earnings Release
9. WuXi PharmaTech Announces First-Quarter 2011 Results
10. WuXi PharmaTech Files 2010 Annual Report on Form 20-F
11. WuXi PharmaTech Schedules First-Quarter 2011 Earnings Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  SI-BONE, Inc., a medical device company that ... a minimally invasive surgical (MIS) device indicated for fusion for ... expansion of its European operations with the formation of a ... as General Manager, Germany.  Mr. Schaber will join former Kyphon ... Europe , Middle East ...
(Date:10/1/2014)...  CVS Health is thanking its 26,000 pharmacists during ... the way health care is delivered to increase access, ... pharmacies, mail service pharmacies and specialty pharmacies nationwide.  ... to CVS Health to reflect our broader health care ... to shape the future of health," said Larry ...
(Date:10/1/2014)... Switzerland , October 1, 2014 /PRNewswire/ ... Clinical Genomics and Next Generation Sequencing (NGS) data analysis, ... to run full cystic fibrosis analysis in a single ... and characterisation of all types of variants in a ... Until now, it has not been possible to ...
Breaking Medicine Technology:SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
... 2011 Reportlinker.com announces that a new market ... The Outlook for Medical Devices in ... http://www.reportlinker.com/p0559145/The-Outlook-for-Medical-Devices-in- Brazil-Russia-India--China.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Managed_care 4 Key Markets ... BRAZIL: Medical Market Size US$3.6 ...
... announces that a new market research report is available in ... in Central & Eastern Europe http://www.reportlinker.com/p0192646/The-Outlook-for-Medical-Devices-in-Central--Eastern-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Managed_care ... Bulgaria Croatia ... Poland Romania Russia ...
Cached Medicine Technology:The Outlook for Medical Devices in Brazil, Russia, India & China 2The Outlook for Medical Devices in Brazil, Russia, India & China 3The Outlook for Medical Devices in Brazil, Russia, India & China 4The Outlook for Medical Devices in Central & Eastern Europe 2The Outlook for Medical Devices in Central & Eastern Europe 3The Outlook for Medical Devices in Central & Eastern Europe 4The Outlook for Medical Devices in Central & Eastern Europe 5
(Date:10/1/2014)... protein beta-amyloid is strongly associated with Alzheimer,s disease; however, ... peptide is the causal agent of the onset and ... confirmation is that beta-amyloid is not harmful when found ... when it self-assembles to form the so-called amyloid fibrils ... beta-amyloid alone, but with multiple ones because each aggregate ...
(Date:10/1/2014)... new research study published today in the Journal ... patients older than 50 years with moderate or severe ... , Researchers from the University of Melbourne randomly assigned ... pain to no acupuncture or sham or pretend laser ... with participants and acupuncturists blinded to laser and sham ...
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... BOSTON (October 1, 2014) Despite a policy ... with developmental disabilities, this vulnerable population continues to ... of The Journal of the American Dental ... Medicine and Tufts University School of Dental Medicine ... factors influencing at-home oral care provided by caregivers ...
(Date:10/1/2014)... 2014 Familylifeinsurancequotes.org has released a ... for senior citizens. , Senior citizens can qualify ... sell coverage to seniors who are over 50 years ... without taking a medical examination. , Term life insurance ... senior clients can qualify. Having life insurance during retirement ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2
... an Army leader and a military surgeon are among the ... the Henry M. Jackson Foundation for the Advancement of Military ... which will take place at the National Museum of Women ... by service members, veterans and civilians who are working together ...
... News) -- Prenatal diagnosis, early surgery and well-coordinated care by ... cleft lip and/or cleft palate, experts say. Cleft lip ... pregnancy when the roof of the mouth fails to fuse ... United States each year and is the second most common ...
... Tierney, M.D., president and CEO of the Regenstrief Institute ... Indiana University School of Medicine, received a 2011 Distinguished ... and Education Meeting on April 28 in Washington, DC. ... Achievement and Contribution to Clinical and Translational Science. He ...
... A gene known to be important in cardiac development ... result in obstruction of the left ventricular outflow tract. ... Nationwide Children,s Hospital and appearing in the journal ... outflow tract (LVOT) malformations, including aortic valve stenosis, coarctation ...
... Australia and Europe. Large resources are set aside for research ... the research field is still new but researchers from ... years ago the Norwegian health care system had a low ... sectors", says Professor Karina Aase at the University of Stavanger. ...
... in powerful positions are just as likely as men to cheat ... that men are more likely than women to cheat on their ... gender, according to the study published April 28 in the journal ... research in the past that indicates that gender is the strongest ...
Cached Medicine News:Health News:Dinner to honor icons of military medicine 2Health News:Early Surgery Boosts Outcomes for Babies With Cleft Palate 2Health News:Tierney named 2011 Clinical and Translational Research Distinguished Investigator 2Health News:Study identifies second gene associated with specific congenital heart defects 2Health News:Sustaining vulnerable lives 2Health News:Sustaining vulnerable lives 3Health News:Powerful Women as Likely to Cheat as Men, Study Finds 2
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
Medicine Products: